1-15 of 15
Jordan Schecter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Mario Boccadoro, Sosana Delimpasi, MD, Meral Beksac, MD, Eirini Katodritou, MD, Philippe Moreau, MD, Luca Baldini, MD PhD, Argiris Symeonidis, MD PhD, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, MD PhD, Hermann Einsele, MD, Ioannis Orfanidis, Tahamtan Ahmadi, MD PhD, Jon Ukropec, PhD, Tobias Kampfenkel, MD, Jordan Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, MD PhD, Robin Carson, MD BA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135874
Published: 2020
Journal Articles

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodriguez-Otero, Luis Pineiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan Schecter, Sagar Lonial, Philippe Moreau
Journal: Blood
Blood (2019) 134 (5): 421–431.
https://doi.org/10.1182/blood.2019000722
Published: 2019
Journal Articles

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Sagar Lonial, MD, Jesus F. San-Miguel, MD, Joaquín Martínez-Lopez, Maria-Victoria Mateos, MD, Joan Blade, Lotfi Benboubker, MD, Albert Oriol, MD, Bertrand Arnulf, Ajai Chari, Luis Pineiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan Schecter, Philippe Moreau, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1869.
https://doi.org/10.1182/blood.V130.Suppl_1.1869.1869
Published: 2017
Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Meletios A. Dimopoulos, Darrell J. White, MD, Lofti Benboubker, MD, Gordon Cook, MD PhD, Merav Leiba, James Morton, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Kihyun Kim, Naoki Takezako, MD PhD, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 739.
https://doi.org/10.1182/blood.V130.Suppl_1.739.739
Published: 2017
Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3110.
https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110
Published: 2017
Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Niels WCJ Van De Donk, Homer Adams, III, Greet Vanhoof, Jakub Krejcik, MD, Koen Van der Borght, Tineke Casneuf, PhD, Tina Smets, Amy Axel, Yann Abraham, Hugo Ceulmans, Frederik Stevenaert, Saad Z Usmani, MD, Torben Plesner, MD, Sagar Lonial, MD, Berris van Kessel-Welmers, Henk M Lokhorst, Tuna Mutis, PhD, Nizar J. Bahlis, MD, Jordan Schecter, Christopher Chiu, Hervé Avet-Loiseau, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3124.
https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124
Published: 2017
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Andrew Spencer, MD, Vania T M Hungria, MD PhD, Maria-Victoria Mateos, MD, Ajay Nooka, MDMPH, Jane Estell, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Piruntha Thiyagarajah, William Deraedt, Christopher Chiu, Jordan Schecter, Katja C. Weisel
Journal: Blood
Blood (2017) 130 (Supplement 1): 3145.
https://doi.org/10.1182/blood.V130.Suppl_1.3145.3145
Published: 2017
Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1824.
https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824
Published: 2017
Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1828.
https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828
Published: 2017
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1852.
https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852
Published: 2017
Journal Articles

Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

Maria-Victoria Mateos, MD PhD, Jane Estell, B.MD(Honours), FRACP, FRCPA, Wolney Barreto, PhD, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Ajay Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 1150.
https://doi.org/10.1182/blood.V128.22.1150.1150
Published: 2016
Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens
Journal: Blood
Blood (2016) 128 (22): 3340.
https://doi.org/10.1182/blood.V128.22.3340.3340
Published: 2016
Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 246.
https://doi.org/10.1182/blood.V128.22.246.246
Published: 2016
Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3313.
https://doi.org/10.1182/blood.V128.22.3313.3313
Published: 2016
Journal Articles

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

Philippe Moreau, MD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD PhD, Javier de la Rubia, MD PhD, Thierry Facon, MD, Raymond L. Comenzo, MD, Joseph W. Fay, MD, Xiang Qin, MS, Tara Masterson, MS, Jordan Schecter, MD, Tahamtan Ahmadi, MD, Jesus San Miguel, MD PhD
Journal: Blood
Blood (2014) 124 (21): 176.
https://doi.org/10.1182/blood.V124.21.176.176
Published: 2014